{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT04318600",
      "OrgStudyIdInfo": {
        "OrgStudyId": "2014001"
      },
      "Organization": {
        "OrgFullName": "Yan'an Affiliated Hospital of Kunming Medical University",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Allogeneic Amniotic Mesenchymal Stem Cell Therapy for Lupus Nephritis",
      "OfficialTitle": "Allogeneic Amniotic Mesenchymal Stem Cell Therapy for Lupus Nephritis"
    },
    "StatusModule": {
      "StatusVerifiedDate": "January 2014",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "January 1, 2014",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "March 1, 2017",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "January 1, 2019",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "March 11, 2020",
      "StudyFirstSubmitQCDate": "March 20, 2020",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "March 24, 2020",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "March 20, 2020",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "March 24, 2020",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Yan'an Affiliated Hospital of Kunming Medical University",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "The First People's Hospital of Yunnan",
            "CollaboratorClass": "OTHER"
          }
        ]
      }
    },
    "OversightModule": {
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "This study would further evaluate the safety and efficacy of human amniotic mesenchymal stem cell (hA-MSC) for the treatment of lupus nephritis (LN).",
      "DetailedDescription": "Eleven patients with WHO class III, IV or V LN were given hA-MSC (Peripheral intravenous infusion, dose 1×106/kg cells, once every month for three times). At the same time, five patients with LN who were not given hA-MSC as the blank control group. All patients did not received intravenous corticosteroids pulse therapy, but the use of oral corticosteroids and intravenous cyclophosphamide, or oral mycophenolate mofetil, tacrolimus , leflunomide were allowed."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Lupus Nephritis",
          "Mesenchymal Stem Cells"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Lupus Nephritis",
          "Human Amniotic Mesenchymal Stem Cell",
          "cell therapy",
          "clinical trail"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Non-Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Single",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "16",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "human amniotic mesenchymal stem cell treatment group",
            "ArmGroupType": "Experimental",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: human amniotic mesenchymal stem cell"
              ]
            }
          },
          {
            "ArmGroupLabel": "blank control group",
            "ArmGroupType": "No Intervention"
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "human amniotic mesenchymal stem cell",
            "InterventionDescription": "human amniotic mesenchymal stem cell (hA-MSC) for the treatment of lupus nephritis patients with WHO class III, IV or V LN were given hA-MSC (Peripheral intravenous infusion, dose 1×106/kg cells, once every month for three times).",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "human amniotic mesenchymal stem cell treatment group"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Incidence of Adverse Events",
            "PrimaryOutcomeDescription": "The patient's discomfort and clinical symptoms during the study were recorded, as well as the related laboratory test indicators and physical examination abnormalities of the subjects during the study. Describe the association with Amniotic mesenchymal stem cell therapy and calculate the incidence of treatment-related acute and chronic adverse events.",
            "PrimaryOutcomeTimeFrame": "60 weeks"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Changes in 24h urine protein quantification before and after treatment；",
            "SecondaryOutcomeDescription": "24-hour urinary protein quantification from baseline to 60 weeks of treatment.",
            "SecondaryOutcomeTimeFrame": "60 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Changes in eGFR before and after treatment;",
            "SecondaryOutcomeDescription": "changes in estimated glomerular filtration rate (eGFR) from baseline to 60 weeks of treatment.",
            "SecondaryOutcomeTimeFrame": "60 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Changes in SLEDAI score before and after treatment；",
            "SecondaryOutcomeDescription": "changes in SLEDAI score from baseline to 60 weeks of treatment. SLEDAI score: 0~4 points basically no activity;5-9 minutes light activity;10-14 minutes of moderate activity;≥15 minutes of severe activity.",
            "SecondaryOutcomeTimeFrame": "60 weeks"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Enrollment criteria:\n\nAdult patients (age 14-60 years) who were diagnosed as lupus nephritis, regardless of gender, uncontrolled disease course;\nPathological examination of puncture biopsy resulting in diagnosis of type II, III, or IV lupus nephritis;\nSLEDAI score >8;\nproteinuria greater than 1 g/day and active urinary sediments;\nLupus nephritis treatment according to guidelines and norms before human amniotic mesenchymal stem cells therapy;\nIf there is a possibility of pregnancy in female, must be negative pregnancy test, not in lactation, and confirm that is receiving the method of contraception recognized by the researchers, and agree to maintain the method of contraception throughout the study. Sexually active male patients must agree to the use of an appropriate contraceptive method for birth control from the first administration of the study treatment until 24 weeks after the last administration.\nThe subjects should be fully informed, voluntarily sign the informed consent, and agree to participate in all visits, examinations, and treatments as required by the experimental protocol.\n\nExclusion criteria:\n\nPatients with kidney biopsy diagnosis of type I, VI lupus nephritis or a diagnosis of another glomerular disease;\nPatients with abnormal renal function (serum creatinine ≥ the upper limit of normal);\nPatients with active liver disease or abnormal liver function test results (ALT or AST ≥2 times the upper limit of normal);\nPatients with blood leukocyte count <2.5 × 109/L, hemoglobin <90 g/L, platelet count <100 × 109/L, or those who have other hematologic diseases (severe anemia, idiopathic thrombocytopenic purpura, splenomegaly, coagulation dysfunction, etc.);\nPatients with serious and unstable cardiovascular or cerebrovascular diseases (unstable angina pectoris, coronary artery disease, cerebrovascular disease, transient ischemic attack, congestive heart failure, etc.), acute and difficult to control the disease, after treatment has not been effectively controlled severe hypertension (blood pressure >160/100 mm Hg), or organ transplantation;\nPatients with uncontrolled infection;\nPatients with tumors or abnormal tumor marker levels; 8. Patients with blood-borne diseases (i.e., HIV, syphilis, hepatitis B, and hepatitis C);\nPregnancy, the potential for pregnancy, or lactation;\nPatients with a history of allergy, especially patients allergic to human blood albumin;\nPatients with mental illness affecting their voluntarism, ability to make decisions, and ability to communicate；\nA history of alcoholism or known drug addiction in the last 2 years;\nParticipation in another clinical trial within the last 3 months;\nPatients judged inappropriate for this study by the physicians.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "14 Years",
      "MaximumAge": "60 Years",
      "StdAgeList": {
        "StdAge": [
          "Child",
          "Adult"
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000009393",
            "ConditionMeshTerm": "Nephritis"
          },
          {
            "ConditionMeshId": "D000008181",
            "ConditionMeshTerm": "Lupus Nephritis"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000007674",
            "ConditionAncestorTerm": "Kidney Diseases"
          },
          {
            "ConditionAncestorId": "D000014570",
            "ConditionAncestorTerm": "Urologic Diseases"
          },
          {
            "ConditionAncestorId": "D000005921",
            "ConditionAncestorTerm": "Glomerulonephritis"
          },
          {
            "ConditionAncestorId": "D000008180",
            "ConditionAncestorTerm": "Lupus Erythematosus, Systemic"
          },
          {
            "ConditionAncestorId": "D000003240",
            "ConditionAncestorTerm": "Connective Tissue Diseases"
          },
          {
            "ConditionAncestorId": "D000001327",
            "ConditionAncestorTerm": "Autoimmune Diseases"
          },
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M11490",
            "ConditionBrowseLeafName": "Nephritis",
            "ConditionBrowseLeafAsFound": "Nephritis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10330",
            "ConditionBrowseLeafName": "Lupus Nephritis",
            "ConditionBrowseLeafAsFound": "Lupus Nephritis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9850",
            "ConditionBrowseLeafName": "Kidney Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16471",
            "ConditionBrowseLeafName": "Urologic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8183",
            "ConditionBrowseLeafName": "Glomerulonephritis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10329",
            "ConditionBrowseLeafName": "Lupus Erythematosus, Systemic",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5616",
            "ConditionBrowseLeafName": "Connective Tissue Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M3781",
            "ConditionBrowseLeafName": "Autoimmune Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T3523",
            "ConditionBrowseLeafName": "Lupus Nephritis",
            "ConditionBrowseLeafAsFound": "Lupus Nephritis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "T2525",
            "ConditionBrowseLeafName": "Glomerulonephritis",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BXS",
            "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC17",
            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    }
  }
}